GRDX

GridAI Technologies Corp.

HealthcareBiotechnologyUSUSDPeers →

$6.35

LiveJun 05, 2026

AI Brief

Market cap

$21.35M

52w range

1.08 – 6.93

P / E

—

EPS

—

Volume

121.18K

Revenue · FY

—

Overview Profile Themes Prices Insiders Sentiment ESG

Explain this page

Arphra AIPlain-English read on GridAI Technologies Corp.’s valuation

Business description

· company · SEC profile

GridAI Technologies Corp.

GridAI Technologies Corp. is a clinical stage biopharmaceutical company, which engages in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its pipeline includes Latiglutenase, Capeserod, Adrulipase, and Niclosamide. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.

Founded

—

IPO

Oct 11, 2016

Employees

Boca Raton, FL

CEO

Jason David Sawyer

CFO

—

Exchange

NASDAQ

Fiscal year

—

Identifiers

· company_identifiers

CIK0001604191

CUSIP33749P507

ISINUS33749P5070

FIGIGRDX US

LEI—